Global Idiopathic Pulmonary Fibrosis market

The Idiopathic Pulmonary Fibrosis Market is Forecast to Show High Growth until 2016.

With 200,000 patients in the US and Europe and over 5,000,000 world wide and no approved therapy, IPF represents a huge un-met medical need. The global idiopathic pulmonary fibrosis (IPF) market was valued at $2.0 billion in 2009. It is expected to increase with a compound annual growth rate (CAGR) of 25.1% from 2009 to 2016.